α-it

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.

Tovetumab (MEDI-575) is a fully human monoclonal antibody that exhibits high selectivity for platelet-derived growth factor receptor alpha (PDGFRα). it functions by specifically inhibiting PDGFRα signal transduction pathways, and it is currently being utilized in clinical research for the treatment of aggressive malignancies including glioblastoma and non-small cell lung cancer (NSCLC).

Tengonermin (ARENEGYR), a vascular-targeting compound, comprises human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. It enhances intratumoral chemotherapy delivery and T-cell infiltration by altering the tumor microenvironment [1] [2].

Suvratoxumab (MEDI4893) is a high-affinity, long-acting humanized IgG1κ anti-α-toxin monoclonal antibody. It effectively neutralizes α-toxin, a principal virulence factor of S. aureus, enhancing survival and diminishing lung injury in an immunocompromised mouse model of pneumonia. Additionally, Suvratoxumab augments the antibacterial efficacy of Vancomycin and Linezolid [1] [2] [3].

Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA). This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-eribulin through reduced interchain disulfide bonds, with an agent-to-antibody ratio of 4.0, demonstrating potent antitumor activity against FRA-positive cells in vitro.

Ifinatamab is a humanised monoclonal immunoglobulin that targets and inhibits the B7-H3 protein. Ifinatamab can be used to synthesise the ADC drug Ifinatamab deruxtecan for the treatment of small cell lung cancer (SCLC).

Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis.

QX006N is a humanized monoclonal antibody inhibitor targeting the human interferon α/β receptor 1 (IFNAR1). It is promising for research in systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases.

BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin 23 (IL-23). It reduces IL-23-induced STAT3 phosphorylation, inhibits Th17 cell differentiation, and suppresses the release of pro-inflammatory cytokines such as IL-17 and TNF-α. BMS-986010 shows promise in research on autoimmune diseases, including psoriasis and Crohn's disease.

Moflerafusp alfa is a fusion protein that targets the human signal-regulatory protein alpha (SIRPα) variant V2 D1 domain and human programmed death-ligand 1 (PD-L1). It shows potential for research in various cancer treatments.

BI-1808 is a human IgG1 monoclonal antibody targeting TNFR2. It blocks the interaction between TNFR2 and its ligand TNF-α, leading to FcγR-dependent regulatory T cell depletion and facilitating the expansion of intratumoral CD8+ T cells.